[HTML][HTML] MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
J Bhin, J Yemelyanenko, X Chao… - Journal of Experimental …, 2023 - rupress.org
Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for breast
cancer treatment. However, low response rates and development of resistance to PI3K–AKT …
cancer treatment. However, low response rates and development of resistance to PI3K–AKT …
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
J Bhin, J Yemelyanenko, X Chao… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Targeting the PI3K-AKT-mTOR pathway is a promising therapeutic strategy for breast cancer
treatment. However, low response rates and development of resistance to PI3K-AKT-mTOR …
treatment. However, low response rates and development of resistance to PI3K-AKT-mTOR …
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
J Bhin, J Yemelyanenko… - Journal of …, 2023 - researchinformation.amsterdamumc …
Abstract Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for
breast cancer treatment. However, low response rates and development of resistance to …
breast cancer treatment. However, low response rates and development of resistance to …
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
J Bhin, J Yemelyanenko, X Chao, S Klarenbeek… - 2023 - ir.ymlib.yonsei.ac.kr
Targeting the PI3K-AKT-mTOR pathway is a promising therapeutic strategy for breast cancer
treatment. However, low response rates and development of resistance to PI3K-AKT-mTOR …
treatment. However, low response rates and development of resistance to PI3K-AKT-mTOR …
[HTML][HTML] MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
J Bhin, J Yemelyanenko, X Chao… - The Journal of …, 2023 - ncbi.nlm.nih.gov
Abstract Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for
breast cancer treatment. However, low response rates and development of resistance to …
breast cancer treatment. However, low response rates and development of resistance to …
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
J Bhin, J Yemelyanenko, X Chao… - The Journal of …, 2023 - europepmc.org
Abstract Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for
breast cancer treatment. However, low response rates and development of resistance to …
breast cancer treatment. However, low response rates and development of resistance to …